Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK2 | O60674 | 2/20 | 0.49 |
| ▸ | JAK1 | P23458 | 2/20 | 0.49 |
| ▸ | TYK2 | P29597 | 2/20 | 0.49 |
| ▸ | JAK3 | P52333 | 2/20 | 0.49 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.38 |
| ▸ | MAOA | P21397 | 2/20 | 0.38 |
| ▸ | MAOB | P27338 | 2/20 | 0.38 |
| ▸ | GLP1R | P43220 | 1/20 | 0.38 |
| ▸ | AOC2 | O75106 | 2/20 | 0.38 |
| ▸ | NAMPT | P43490 | 1/20 | 0.37 |
| ▸ | CNR2 | P34972 | 3/20 | 0.36 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.36 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.36 |
| ▸ | CNR1 | P21554 | 1/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | NR2F2 | P24468 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12697199 | 0.94 | JAK2 (0.47) | JAK2JAK1TYK2JAK3CRBN | |
| SCHEMBL16174392 | 0.84 | AOC2 (0.48) | JAK2JAK1TYK2JAK3MAOA | |
| SCHEMBL12695032 | 0.80 | GLP1R (0.44) | JAK2JAK1TYK2JAK3MAOA | |
| SCHEMBL1782820 | 0.78 | CRBN (0.55) | CRBN | |
| SCHEMBL22212570 | 0.78 | GAA (0.45) | JAK2JAK1TYK2JAK3NAMPT | |
| SCHEMBL12481464 | 0.76 | KDM4E (0.44) | MAOAMAOBAOC2PTGS2LMNA | |
| SCHEMBL16425252 | 0.76 | KCNH2 (0.58) | KCNH2 | |
| Hydrochloric Acid SCHEMBL28375436 | 0.75 | GAA (0.47) | JAK2JAK1TYK2JAK3NAMPT | |
| SCHEMBL23103102 | 0.75 | PTGS1 (0.36) | JAK2JAK1TYK2JAK3MAOA | |
| SCHEMBL2536571 | 0.74 | MAOA (0.40) | CRBNMAOAMAOBGLP1RAOC2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120245136-A1 | CHROMAN-SPIROCYCLIC PIPERIDINE AMIDES AS MODULATORS OF ION CHANNELS | VERTEX PHARMACEUTICALS INCORPORATED | 2012-09-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120245136-A1 | CHROMAN-SPIROCYCLIC PIPERIDINE AMIDES AS MODULATORS OF ION CHANNELS | KCNJ2, KCNJ1, KCNC1 | JAK2 3502/4885JAK1 4767/4885TYK2 4093/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.